{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:26:25Z","timestamp":1758039985912,"version":"3.44.0"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myotonic Dystrophy (DM) is a hereditary muscle disorder characterized by progressive muscle weakness, myotonia, and multi-system dysfunction. Based on clinical and genetic features, DM can be classified into Type 1 (Type 1 Myotonic Dystrophy, DM1) and Type 2 (Type 2 Myotonic Dystrophy, DM2), with DM1 being the most common subtype in adulthood. Diabetes, a metabolic disease, is defined by persistent hyperglycemia, typically resulting from insufficient insulin secretion or impaired insulin action. Among the various forms of diabetes, Type 2 Diabetes (T2DM) has the highest prevalence, accounting for approximately 90% of all cases. Research has shown that individuals with Myotonic Dystrophy Type 1 (DM1) often experience comorbid Type 2 Diabetes (T2DM), a phenomenon that not only significantly increases the clinical burden but is also closely associated with poor prognosis, severely impacting patients\u2019 quality of life. This review provides a comprehensive analysis of the latest research on insulin resistance in DM1 patients, shedding light on the underlying mechanisms of DM1-related T2DM. Additionally, it explores the common comorbidities shared by DM1 and T2DM, including those affecting the muscular, respiratory, cardiovascular, endocrine, and nervous systems, as well as cancer and depression. Finally, this article summarizes the most recent therapeutic strategies for managing DM1 with T2DM, focusing on glucose-lowering medications combined with emerging targeted therapies that address the core pathophysiology of DM1, showing promising preclinical outcomes. This review aims to provide a theoretical foundation for future research and clinical practice in the management of DM1 complicated by T2DM.<\/jats:p>","DOI":"10.3389\/fneur.2025.1640563","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:26:21Z","timestamp":1757568381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaona","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muyang","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000524734","article-title":"Global prevalence of myotonic dystrophy: an updated systematic review and Meta-analysis","volume":"56","author":"Liao","year":"2022","journal-title":"Neuroepidemiology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nrl.2019.01.001","article-title":"Clinical guide for the diagnosis and follow-up of myotonic dystrophy type 1, MD1 or steinert\u2019s disease","volume":"35","author":"Guti\u00e9rrez Guti\u00e9rrez","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1212\/WNL.0000000000011425","article-title":"Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program","volume":"96","author":"Johnson","year":"2021","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.21934","article-title":"Survival and CTG repeat expansion in adults with myotonic dystrophy type 1","volume":"43","author":"Groh","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.11817\/j.issn.1672-7347.2023.220599","article-title":"A case of myotonic dystrophy type 1 initially diagnosed with early-onset diabetes mellitus","volume":"48","author":"Jinjing","year":"2023","journal-title":"J Central South Univ"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"109118","DOI":"10.1016\/j.diabres.2021.109118","article-title":"IDF diabetes atlas: global estimates of undiagnosed diabetes in adults for 2021","volume":"183","author":"Ogurtsova","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.19538\/j.nk2021090106","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition)","volume":"37","year":"2021","journal-title":"Chin J Endocrinol Metabol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ijc.3280","article-title":"Diabetes, metformin and cancer risk in myotonic dystrophy type I","volume":"147","author":"Alsaggaf","year":"2020","journal-title":"Int J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0148264","DOI":"10.1371\/journal.pone.0148264","article-title":"Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: A Nationwide multiple databases cross-sectional observational study","volume":"11","author":"Dogan","year":"2016","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejpn.2023.12.001","article-title":"Myotonic dystrophy type 1 (Steinert disease): 29 years of experience at a tertiary pediatric hospital","volume":"48","author":"Cascais","year":"2023","journal-title":"Eur J Paediatr Neuro"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/hmg\/ddp058","article-title":"Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy","volume":"18","author":"Osborne","year":"2009","journal-title":"Hum Mol Genet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"9 303","DOI":"10.3389\/fneur.2018.00303","article-title":"Core clinical phenotypes in myotonic dystrophies","volume":"9","author":"Wenninger","year":"2018","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","article-title":"Myotonic dystrophy: diagnosis, management and new therapies","volume":"27","author":"Turner","year":"2014","journal-title":"Curr Opin Neurol"},{"volume-title":"Myotonic dystrophy type 1(GeneReviews\u00ae[internet])","year":"1993","author":"Adam","key":"ref15"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/1097-4598(200012)23:12<1789:aid-mus2>3.0.co;2-4","article-title":"Clinical and genetic heterogeneity in myotonic dystrophies","volume":"23","author":"Meola","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jns.2008.08.037","article-title":"A cross-sectional study for glucose intolerance of myotonic dystrophy","volume":"276","author":"Matsumura","year":"2009","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ng704","article-title":"Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy","volume":"29","author":"Savkur","year":"2001","journal-title":"Nat Genet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3969\/j.issn.1673-7202.2021.11.005","article-title":"Research progress on the pathogenesis of insulin resistance","volume":"16","author":"Liu","year":"2021","journal-title":"World J Trad Chin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3969\/j.issn.1671-7856.2013.08.014","article-title":"NF-\u03baB signaling pathway and insulin resistance","volume":"23","author":"Yichao","year":"2013","journal-title":"Chin J Compar Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"10 1229","DOI":"10.3389\/fneur.2019.01229","article-title":"Insulin signaling as a key moderator in myotonic dystrophy type 1","volume":"10","author":"Nieuwenhuis","year":"2019","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0214254","DOI":"10.1371\/journal.pone.0214254","article-title":"Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies","volume":"14","author":"Renna","year":"2019","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"22457","DOI":"10.1074\/jbc.M802803200","article-title":"The RNA-binding protein CUGBP1 regulates stability of tumor necrosis factor mRNA in muscle cells: implications for myotonic dystrophy","volume":"283","author":"Zhang","year":"2008","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1128\/MCB.19.5.3278","article-title":"Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells","volume":"19","author":"Frasca","year":"1999","journal-title":"Mol Cell Biol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1530\/ERC-11-0074","article-title":"Insulin receptor and cancer","volume":"18","author":"Belfiore","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10072-016-2805-5","article-title":"Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects","volume":"38","author":"Meola","year":"2017","journal-title":"Neurol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/genes11091109","article-title":"An overview of alternative splicing defects implicated in myotonic dystrophy type I","volume":"11","author":"L\u00f3pez-Mart\u00ednez","year":"2020","journal-title":"Genes (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.1093\/nar\/gku767","article-title":"MBNL proteins and their target RNAs, interaction and splicing regulation","volume":"42","author":"Konieczny","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/ncomms3044","article-title":"Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules","volume":"4","author":"Childs-Disney","year":"2013","journal-title":"Nat Commun"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum Mol Genet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nmd.2017.10.007","article-title":"Mitochondrial dysfunction in myotonic dystrophy type 1","volume":"28","author":"Gramegna","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.18632\/aging.103022","article-title":"Myotonic dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin","volume":"12","author":"Garc\u00eda-Puga","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41598-021-03901-9","article-title":"Distribution of alternative untranslated regions within the mRNA of the CELF1 splicing factor affects its expression","volume":"12","author":"Kajdasz","year":"2022","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010094","article-title":"Correction of RNA-binding protein CUGBP1 and GSK3\u03b2 signaling as therapeutic approach for congenital and adult myotonic dystrophy type 1","volume":"21","author":"Timchenko","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4161\/rna.28799","article-title":"Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1","volume":"11","author":"Wojciechowska","year":"2014","journal-title":"RNA Biol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol Cell"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11010-013-1681-z","article-title":"Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2","volume":"380","author":"Santoro","year":"2013","journal-title":"Mol Cell Biochem"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10072-009-0048-4","article-title":"Comparative transcriptional and biochemical studies in muscle of myotonic dystrophies (DM1 and DM2)","volume":"30","author":"Salvatori","year":"2009","journal-title":"Neurol Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3727\/000000006781510705","article-title":"Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2","volume":"13","author":"Botta","year":"2007","journal-title":"Gene Expr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbadis.2006.05.013","article-title":"Myotonic dystrophy: emerging mechanisms for DM1 and DM2","volume":"1772","author":"Cho","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.nmd.2004.09.012","article-title":"RNA pathogenesis of the myotonic dystrophies","volume":"15","author":"Day","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e0184987","DOI":"10.1371\/journal.pone.0184987","article-title":"Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle","volume":"12","author":"Renna","year":"2017","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e1134","DOI":"10.1371\/journal.pone.0001134","article-title":"Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action","volume":"2","author":"Llagostera","year":"2007","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.febslet.2009.05.043","article-title":"High-fat diet induced adiposity and insulin resistance in mice lacking the myotonic dystrophy protein kinase","volume":"583","author":"Llagostera","year":"2009","journal-title":"FEBS Lett"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ajcn\/80.2.357","article-title":"Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1","volume":"80","author":"Perseghin","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1530\/EJE-11-0537","article-title":"Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1","volume":"165","author":"Daniele","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/sj.ijo.0802078","article-title":"Testosterone and diurnal rhythmicity of leptin, TNF-alpha and TNF-II receptor in insulin-resistant myotonic dystrophy patients","volume":"26","author":"Johansson","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mus.21484","article-title":"Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy","volume":"41","author":"Shieh","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.2337\/diacare.26.7.2112","article-title":"Contribution of abnormal insulin secretion and insulin resistance to the pathogenesis of type 2 diabetes in myotonic dystrophy","volume":"26","author":"Perseghin","year":"2003","journal-title":"Diabetes Care"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00415-014-7570-x","article-title":"Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases","volume":"262","author":"Bouchard","year":"2014","journal-title":"J Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/(sici)1097-4598(200004)23:4<529::aid-mus11>3.0.co;2-y","article-title":"Contractile properties of single muscle fibers in myotonic dystrophy","volume":"23","author":"Krivickas","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref52","first-page":"13","article-title":"Congenital myotonic dystrophy: variability in muscle involvement and histopathological process","volume":"15","author":"Kuo","year":"2006","journal-title":"Acta Neurol Taiwanica"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/09593985.2022.2057375","article-title":"Morphological and functional changes in skeletal muscle in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"39","author":"Filgueiras","year":"2022","journal-title":"Physiother Theory Pract"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc11-2202","article-title":"Role of muscle mass and muscle quality in the association between diabetes and gait speed","volume":"35","author":"Volpato","year":"2012","journal-title":"Diabetes Care"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/978-1-4614-0653-2_18","article-title":"Myotonic dystrophy type 1 or Steinert's disease","volume":"724","author":"Romeo","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00223-020-00742-y","article-title":"Type 2 diabetes mellitus is associated with increased risk of sarcopenia: A systematic review and Meta-analysis","volume":"107","author":"Anagnostis","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12883-021-02264-y","article-title":"Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia","volume":"21","author":"Hofmeister","year":"2021","journal-title":"BMC Neurol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.4103\/jfmpc.jfmpc_838_20","article-title":"Thyroid dysfunction in patients with type 2 diabetes mellitus and its association with diabetic complications","volume":"9","author":"Mehalingam","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0022-510x(79)90015-7","article-title":"Myotonic dystrophy associated with thyroid disease","volume":"43","author":"Rioperez","year":"1979","journal-title":"J Neurol Sci"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/390534","article-title":"The relationship between type 2 diabetes mellitus and related thyroid diseases","volume":"2013","author":"Wang","year":"2013","journal-title":"J Diabetes Res"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12020-014-0474-9","article-title":"Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) position statement: diabetes mellitus and thyroid disorders: recommendations for clinical practice","volume":"49","author":"Guastamacchia","year":"2014","journal-title":"Endocrine"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1210\/clinem\/dgab430","article-title":"Endocrine dysfunction in patients with myotonic dystrophy","volume":"106","author":"Winters","year":"2021","journal-title":"J Clin Endocr Metab"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.14341\/probl9775","article-title":"Autoimmune polyglandular disorders in myotonic dystrophy","volume":"65","author":"Troshina","year":"2019","journal-title":"Probl Endokrinol (Mosk)"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00415-011-6277-5","article-title":"Endocrine function in 97 patients with myotonic dystrophy type 1","volume":"259","author":"\u00d8rngreen","year":"2012","journal-title":"J Neurol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"11 277","DOI":"10.3389\/fneur.2020.00277","article-title":"Multisystemic impairments in 93 Chinese patients with myotonic dystrophy type 1","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1385\/ENDO:18:2:105","article-title":"The endocrine system in diabetes mellitus","volume":"18","author":"Alrefai","year":"2002","journal-title":"Endocrine"},{"key":"ref67","first-page":"507","article-title":"Endocrine diseases and diabetes","volume":"143","author":"Brunov\u00e1","year":"2004","journal-title":"Cas Lek Cesk"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.7860\/JCDR\/2013\/6550.3339","article-title":"Alveolar gas exchange and pulmonary functions in patients with type II diabetes mellitus","volume":"7","author":"A","year":"2013","journal-title":"J Clin Diagn Res"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.rmed.2011.03.010","article-title":"Type II diabetes mellitus is associated with decreased measures of lung function in a clinical setting","volume":"105","author":"Klein","year":"2011","journal-title":"Respir Med"},{"key":"ref70","first-page":"603","article-title":"Pulmonary complications in diabetes mellitus","volume":"23","author":"Ali","year":"2014","journal-title":"Mymensingh Med J"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1046\/j.1464-5491.2003.00994.x","article-title":"Respiratory failure secondary to diabetic neuropathy affecting the phrenic nerve","volume":"20","author":"Tang","year":"2003","journal-title":"Diabetic Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1136\/jnnp.2008.165035","article-title":"A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1","volume":"80","author":"Laberge","year":"2009","journal-title":"J Neurol Neurosur Psychiatry"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.nmd.2011.08.010","article-title":"Sleep breathing disorders in 40 Italian patients with myotonic dystrophy type 1","volume":"22","author":"Pincherle","year":"2011","journal-title":"Neuromuscul Disord"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/1753-0407.12225","article-title":"Type 2 diabetes affects sleep quality by disrupting the respiratory function","volume":"7","author":"Colbay","year":"2014","journal-title":"J Diabetes"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.nmd.2018.12.002","article-title":"Respiratory dysfunction in myotonic dystrophy type 1: a systematic review","volume":"29","author":"Hawkins","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nmd.2019.10.011","article-title":"Characteristics of respiratory muscle involvement in myotonic dystrophy type 1","volume":"30","author":"Henke","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3969\/j.issn.1005-9202.2018.11.044","article-title":"Changes in respiratory function and clinical characteristics of patients with myotonic dystrophy type 1","volume":"38","author":"Aihua","year":"2018","journal-title":"Chin J Gerontol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e15321","DOI":"10.1097\/MD.0000000000015321","article-title":"Clinical implication of maximal voluntary ventilation in myotonic muscular dystrophy","volume":"98","author":"Suh","year":"2019","journal-title":"Medicine"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"10 681","DOI":"10.3389\/fneur.2019.00681","article-title":"Two adult siblings with myotonic dystrophy type 1 with different phenotypes presenting with chronic respiratory insufficiency and sleep apnea syndrome","volume":"10","author":"Kohno","year":"2019","journal-title":"Front Neurol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.nmd.2015.02.006","article-title":"Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level","volume":"25","author":"Poussel","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1097\/CRD.0b013e31821950f9","article-title":"Myotonic dystrophies and the heart","volume":"20","author":"Chaudhry","year":"2012","journal-title":"Cardiol Rev"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/eurheartj\/ehw569","article-title":"Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1","volume":"38","author":"Wahbi","year":"2017","journal-title":"Eur Heart J"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-018-0751-7","article-title":"Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary","volume":"17","author":"Kiss","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ncpcardio0213","article-title":"Therapy insight: cardiovascular complications associated with muscular dystrophies","volume":"2","author":"McNally","year":"2005","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/00365513.2016.1155230","article-title":"Myocardial dysfunction and cardiovascular disease in type 2 diabetes","volume":"76","author":"Ofstad","year":"2016","journal-title":"Scand J Clin Lab Invest"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/ehjci\/jez266","article-title":"Cardiac perfusion, structure, and function in type 2 diabetes mellitus with and without diabetic complications","volume":"21","author":"S\u00f8rensen","year":"2020","journal-title":"Eur Heart J"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"14 1258318","DOI":"10.3389\/fphys.2023.1258318","article-title":"Cardiac involvement in patient-specific induced pluripotent stem cells of myotonic dystrophy type 1: unveiling the impact of voltage-gated sodium channels","volume":"14","author":"Pierre","year":"2023","journal-title":"Front Physiol"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.nmd.2014.11.018","article-title":"Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1","volume":"25","author":"Algalarrondo","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201912450","article-title":"Biophysical mechanisms for QRS- and QTc-interval prolongation in mice with cardiac expression of expanded CUG-repeat RNA","volume":"152","author":"Tylock","year":"2020","journal-title":"J Gen Physiol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"e56616","DOI":"10.15252\/embr.202256616","article-title":"Deregulations of miR-1 and its target Multiplexin promote dilated cardiomyopathy associated with myotonic dystrophy type 1","volume":"24","author":"Souidi","year":"2023","journal-title":"EMBO Rep"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1172\/JCI186416","article-title":"MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model","volume":"135","author":"Hu","year":"2025","journal-title":"J Clin Invest"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.nmd.2003.11.002","article-title":"Cardiovascular autonomic control in myotonic dystrophy type 1: a correlative study with clinical and genetic data","volume":"14","author":"Di Leo","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jnr.21377","article-title":"Myotonic dystrophy 1 in the nervous system: from the clinic to molecular mechanisms","volume":"86","author":"de Le\u00f3n","year":"2008","journal-title":"J Neurosci Res"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/neuroindia.NI_1432_20","article-title":"Myotonic dystrophy type 1 (DM1): clinical characteristics and disease progression in a large cohort","volume":"72","author":"Chawla","year":"2024","journal-title":"Neurol India"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1212\/01.wnl.0000225180.27833.c1","article-title":"Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2)","volume":"67","author":"Gaul","year":"2006","journal-title":"Neurology"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3233\/JND-230083","article-title":"Longitudinal changes in neuropsychological functioning in Japanese patients with myotonic dystrophy type 1: a five year follow-up study","volume":"10","author":"Fujino","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3760\/cma.j.cn311282-20220518-00320","article-title":"Chinese Working Group on Antihypertensive Treatment Targets in Adults with Type 2 Diabetes. Chinese Expert Consensus on the Prevention and Treatment of Cognitive Dysfunction in Patients with Type 2 Diabetes","volume":"38","year":"2022","journal-title":"Chin J Endocrinol Metabol"},{"key":"ref98","first-page":"71","article-title":"Type 2 diabetes mellitus and cerebral small vessel disease (case report)","volume":"277","author":"Sopromadze","year":"2018","journal-title":"Georgian Med News"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00125-007-0602-7","article-title":"Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes","volume":"50","author":"Gold","year":"2007","journal-title":"Diabetologia"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/WNL.0b013e3181d8c35f","article-title":"Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2","volume":"74","author":"Weber","year":"2010","journal-title":"Neurology"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1001\/jama.2011.1796","article-title":"Cancer risk among patients with myotonic muscular dystrophy","volume":"306","author":"Gadalla","year":"2011","journal-title":"JAMA"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/mus.26194","article-title":"Cancer phenotype in myotonic dystrophy patients: results from a meta-analysis","volume":"58","author":"Emparanza","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acn3.50856","article-title":"Benign tumors in myotonic dystrophy type I target disease-related cancer sites","volume":"6","author":"Alsaggaf","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10654-018-0438-0","article-title":"Cancer incidence among Finnish people with type 2 diabetes during 1989-2014","volume":"34","author":"Saarela","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00125-011-2242-1","article-title":"Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias","volume":"54","author":"Johnson","year":"2011","journal-title":"Diabetologia"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3969\/j.issn.1674-4616.2023.04.006","article-title":"Guidelines for the management of chronic diseases of elderly patients with type 2 diabetes mellitus","volume":"15","year":"2023","journal-title":"Res Int Trad Chin West Med"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17010246","article-title":"Increased risk of site-specific cancer in people with type 2 diabetes: a national cohort study","volume":"17","author":"Linkeviciute-Ulinskiene","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"e79851","DOI":"10.1371\/journal.pone.0079851","article-title":"Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis","volume":"8","author":"Gadalla","year":"2013","journal-title":"PLoS One"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jad.2019.03.036","article-title":"Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis","volume":"250","author":"van der Velden","year":"2019","journal-title":"J Affect Disord"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1093\/brain\/awr299","article-title":"The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease","volume":"134","author":"Minnerop","year":"2011","journal-title":"Brain"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3760\/cma.j.cn115791-20210221-00095","article-title":"Guidelines for the prevention and treatment of type 2 diabetes in China (2020 edition)","volume":"13","year":"2021","journal-title":"Chin J Diab"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1758-5996-3-26","article-title":"Depression, glycemic control and type 2 diabetes","volume":"3","author":"Papelbaum","year":"2011","journal-title":"Diabetol Metab Syndr"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaneurol.2017.4778","article-title":"Development and validation of a new scoring system to predict survival in patients with myotonic dystrophy type 1","volume":"75","author":"Wahbi","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms19113615","article-title":"Insulin receptor isoforms in Cancer","volume":"19","author":"Vella","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40618-016-0508-7","article-title":"Insulin, insulin receptors, and cancer","volume":"39","author":"Vigneri","year":"2016","journal-title":"J Endocrinol Investig"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"108233","DOI":"10.1016\/j.diabres.2020.108233","article-title":"Review of methods for detecting glycemic disorders","volume":"165","author":"Bergman","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1038\/mtna.2015.35","article-title":"In vitro and in vivo modulation of alternative splicing by the Biguanide metformin","volume":"4","author":"Laustriat","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1113\/JP282725","article-title":"Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients","volume":"600","author":"Ravel-Chapuis","year":"2022","journal-title":"J Physiol-London"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/brv.12674","article-title":"The hallmarks of myotonic dystrophy type 1 muscle dysfunction","volume":"96","author":"Ozimski","year":"2020","journal-title":"Biol Rev"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.jocmr.2024.101268","article-title":"Effect of metformin on myocardial fibrosis and cardiac function in duchenne muscular dystrophy: a longitudinal cohort study using cardiovascular magnetic resonance","volume":"27","author":"Zhang","year":"2025","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/BF03346357","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in type 2 diabetes management","volume":"30","author":"Crepaldi","year":"2007","journal-title":"J Endocrinol Investig"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4158\/EP12303.RA","article-title":"The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes","volume":"19","author":"Davidson","year":"2013","journal-title":"Endocr Pract"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00592-018-1271-3","article-title":"Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus","volume":"56","author":"Sesti","year":"2019","journal-title":"Acta Diabetol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/jcm13175252","article-title":"Investigation of glucose metabolism by continuous glucose monitoring and validation of dipeptidyl peptidase 4 inhibitor use in patients with myotonic dystrophy type 1","volume":"13","author":"Takada","year":"2024","journal-title":"J Clin Med"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","article-title":"Tolerability of dipeptidyl peptidase-4 inhibitors: a review","volume":"33","author":"Richard","year":"2011","journal-title":"Clin Ther"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/2042098614523031","article-title":"Safety of dipeptidyl peptidase 4 inhibitors: a perspective review","volume":"5","author":"Karagiannis","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12020-015-0811-7","article-title":"Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors","volume":"53","author":"Fiorentino","year":"2015","journal-title":"Endocrine"},{"key":"ref132","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/medicina60121986","article-title":"Impact of DPP-4 inhibitors in patients with diabetes mellitus and heart failure: an in-depth review","volume":"60","author":"Epelde","year":"2024","journal-title":"Medicina (B Aires)"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/cvr\/cvw182","article-title":"Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling","volume":"111","author":"Takada","year":"2016","journal-title":"Cardiovasc Res"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.41058","article-title":"Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis","volume":"72","author":"Soare","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref135","first-page":"287","article-title":"Long-term treatment of diabetes mellitus in myotonic dystrophy with pioglitazone","volume":"45","author":"Yamamoto","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"key":"ref136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1507\/endocrj.k09e-122","article-title":"Dramatic improvement of blood glucose control after pioglitazone treatment in poorly controlled over-weight diabetic patients with myotonic dystrophy","volume":"56","author":"Abe","year":"2009","journal-title":"Endocr J"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1530\/EDM-17-0143","article-title":"Myotonic dystrophy type 1 with diabetes mellitus, mixed hypogonadism and adrenal insufficiency","volume":"2018","author":"Takeshima","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3760\/cma.j.cn115791-20191024-00385","article-title":"Two cases of myotonic dystrophy type 1 diagnosed as first diagnosis of diabetes mellitus: a case report and literature review","volume":"12","author":"Shen","year":"2020","journal-title":"Chin J Diab"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tsch\u00f6p","year":"2023","journal-title":"Diabetologia"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.pharmthera.2022.108270","article-title":"Emerging roles of glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities","volume":"239","author":"Shao","year":"2022","journal-title":"Pharmacol Ther"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.amjms.2024.06.030","article-title":"Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: a case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide","volume":"369","author":"Kato","year":"2024","journal-title":"Am J Med Sci"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"e51352","DOI":"10.7759\/cureus.51352","article-title":"Glucagon-like Peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications","volume":"15","author":"Rajagopal","year":"2023","journal-title":"Cureus"},{"year":"","key":"ref144"},{"year":"","key":"ref145"},{"key":"ref146","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/jgh.16650","article-title":"Gastrointestinal involvement in neuromuscular disorders","volume":"39","author":"Finsterer","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"18551","DOI":"10.1073\/pnas.0903234106","article-title":"Pentamidine reverses the splicing defects associated with myotonic dystrophy","volume":"106","author":"Warf","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1242\/dmm.021428","article-title":"Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction","volume":"8","author":"Chakraborty","year":"2015","journal-title":"Dis Model Mech"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1021\/acs.jmedchem.5b00356","article-title":"Biological efficacy and toxicity of Diamidines in myotonic dystrophy type 1 models","volume":"58","author":"Siboni","year":"2015","journal-title":"J Med Chem"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/pharmaceutics10040195","article-title":"Strategies to obtain encapsulation and controlled release of Pentamidine in mesoporous silica nanoparticles","volume":"10","author":"Peretti","year":"2018","journal-title":"Pharmaceutics"},{"key":"ref151","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00216-018-1107-6","article-title":"Affinity capillary electrophoresis for identification of active drug candidates in myotonic dystrophy type 1","volume":"410","author":"Neaga","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1021\/acsptsci.9b00020","article-title":"Combination treatment of erythromycin and furamidine provides additive and synergistic rescue of mis-splicing in myotonic dystrophy type 1 models","volume":"2","author":"Jenquin","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"102623","DOI":"10.1016\/j.nano.2022.102623","article-title":"Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy","volume":"47","author":"Repellin","year":"2022","journal-title":"Nanomed-Nanotechnol"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"102761","DOI":"10.1016\/j.jaccas.2024.102761","article-title":"Managing myotonic dystrophy type 1 complicated by metabolic syndrome","volume":"29","author":"Pagnoni","year":"2024","journal-title":"JACC Case Rep"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ijms232113359","article-title":"Recent Progress and challenges in the development of antisense therapies for myotonic dystrophy type 1","volume":"23","author":"De Serres-B\u00e9rard","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3969\/j.issn.1009-0959.2024.04.007","article-title":"Research and application of antisense oligonucleotide drugs in the treatment of nervous system diseases","volume":"26","author":"Hu","year":"2024","journal-title":"Chin J Pharma Guide"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1089\/hum.2023.29258.abstracts","article-title":"ESGCT 30th Annual Congress In collaboration with SFTCG and NVGCT Brussels, Belgium October 24\u201327, 2023 Abstracts","volume":"35","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.3233\/JND-249001","article-title":"Abstracts of the 17th UK neuromuscular translational research conference, 17th and 18th April 2024","volume":"11","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1117019109","article-title":"Rnase H-mediated degradation of toxic RNA in myotonic dystrophy type 1","volume":"109","author":"Lee","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/hmg\/ddaa060","article-title":"Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA","volume":"29","author":"Yadava","year":"2020","journal-title":"Hum Mol Genet"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/nar\/gkv163","article-title":"Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy","volume":"43","author":"Wojtkowiak-Szlachcic","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"ref163","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.omtn.2023.04.010","article-title":"Block or degrade? Balancing on- and off-target effects of antisense strategies against transcripts with expanded triplet repeats in DM1","volume":"32","author":"El Boujnouni","year":"2023","journal-title":"Mol Ther Nucleic Acids."},{"key":"ref164","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","article-title":"Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial","volume":"22","author":"Thornton","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J Clin Invest"},{"key":"ref166","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1089\/hum.2022.069","article-title":"Enhanced delivery of ligand-conjugated antisense oligonucleotides (C16-HA-ASO) targeting Dystrophia Myotonica protein kinase transcripts for the treatment of myotonic dystrophy type 1","volume":"33","author":"Ait Benichou","year":"2022","journal-title":"Hum Gene Ther"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"104441.536","DOI":"10.1016\/j.nmd.2024.07.545","article-title":"461p evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1","volume":"43","author":"Larkindale","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"104441.68","DOI":"10.1016\/j.nmd.2024.07.077","article-title":"226P phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1: HARBOR trial design","volume":"43","author":"Fowler","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref169","first-page":"104441.515","article-title":"440P nonclinical data for PGN-EDODM1 demonstrated nuclear delivery, mechanistic and meaningful activity for the potential treatment of DM1 neuromuscular disord","author":"Gilbert","year":"2024"},{"key":"ref170","doi-asserted-by":"publisher","first-page":"104441.546","DOI":"10.1016\/j.nmd.2024.07.555","article-title":"471p interfering with CUG toxic repeats using AAV.U7snRNAs rescue myotonia and splicing defects in myotonic dystrophy type 1","volume":"43","author":"Almeida","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymthe.2024.04.020","article-title":"Oral abstracts","volume":"32","author":"Almeida","year":"2024","journal-title":"Mol Ther"},{"key":"ref172","doi-asserted-by":"publisher","first-page":"104441.513","DOI":"10.1016\/j.nmd.2024.07.522","article-title":"438P knockdown of DMPK in myotonic dystrophy type 1 using CRISPR Cas13","volume":"43","author":"Oh","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"ref173","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.ymthe.2020.10.005","article-title":"Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1","volume":"28","author":"Marsh","year":"2020","journal-title":"Mol Ther"},{"key":"ref174","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms20153689","article-title":"CRISPR\/Cas applications in myotonic dystrophy: expanding opportunities","volume":"20","author":"Raaijmakers","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref175","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","article-title":"CRISPR\/Cas9-mediated deletion of CTG expansions recovers Normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients","volume":"9","author":"Provenzano","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref176","doi-asserted-by":"publisher","first-page":"8275","DOI":"10.1093\/nar\/gky548","article-title":"Efficient CRISPR\/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells","volume":"46","author":"Dastidar","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"ref177","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.ymthe.2019.05.021","article-title":"Genome editing of expanded CTG repeats within the human DMPK gene reduces nuclear RNA foci in the muscle of DM1 mice","volume":"27","author":"Lo Scrudato","year":"2019","journal-title":"Mol Ther"},{"key":"ref178","doi-asserted-by":"publisher","first-page":"e70227","DOI":"10.1002\/ctm2.70227","article-title":"Muscle-specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1","volume":"15","author":"Izzo","year":"2025","journal-title":"Clin Transl Med"},{"key":"ref179","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.omtn.2023.05.007","article-title":"Specific DMPK-promoter targeting by CRISPRi reverses myotonic dystrophy type 1-associated defects in patient muscle cells","volume":"32","author":"Porquet","year":"2023","journal-title":"Mol Ther Nucleic Acids."},{"key":"ref180","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.omtm.2020.05.024","article-title":"Unexpected mutations by CRISPR-Cas9 CTG repeat excision in myotonic dystrophy and use of CRISPR interference as an alternative approach","volume":"18","author":"Ikeda","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref181","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41551-020-00607-7","article-title":"The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1","volume":"5","author":"Batra","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"ref182","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-induced (CTG\u00b7CAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing","volume":"25","author":"van Agtmaal","year":"2017","journal-title":"Mol Ther"},{"key":"ref183","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1089\/hum.2023.059","article-title":"Advances in CRISPR\/Cas9 genome editing for the treatment of muscular dystrophies","volume":"34","author":"Fatehi","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref184","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.omtn.2022.02.003","article-title":"Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model","volume":"27","author":"Overby","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref185","doi-asserted-by":"publisher","first-page":"eadn6525","DOI":"10.1126\/sciadv.adn6525","article-title":"AntimIR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action","volume":"10","author":"Cerro-Herreros","year":"2024","journal-title":"Sci Adv"},{"key":"ref186","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/acscentsci.2c01223","article-title":"Transcriptome-wide studies of RNA-targeted small molecules provide a simple and selective r(CUG)exp degrader in myotonic dystrophy","volume":"9","author":"Gibaut","year":"2023","journal-title":"ACS Cent Sci"},{"key":"ref187","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41551-021-00838-2","article-title":"Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats","volume":"6","author":"Arandel","year":"2022","journal-title":"Nat Biomed Eng"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1640563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:26:29Z","timestamp":1757568389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1640563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":187,"alternative-id":["10.3389\/fneur.2025.1640563"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1640563","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"1640563"}}